LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Zepbound is the brand name for tirzepatide, a medication FDA-approved for chronic weight management in adults with obesity or overweight with weight-related health conditions. Many patients wonder if there are alternative names for this medication. The answer is yes—tirzepatide is also marketed as Mounjaro for type 2 diabetes treatment. Understanding these different names, their specific uses, and how they relate to the same active ingredient helps patients navigate prescriptions, insurance coverage, and pharmacy dispensing. This guide clarifies the naming conventions, explains why one drug has multiple brand names, and provides essential information for identifying tirzepatide medications safely.
Quick Answer: Zepbound's generic name is tirzepatide, which is also marketed as Mounjaro for type 2 diabetes treatment.
Zepbound is the brand name for tirzepatide when prescribed specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition. The generic name—tirzepatide—refers to the active pharmaceutical ingredient, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual mechanism distinguishes tirzepatide from single-receptor agonists in its class.
The US Food and Drug Administration (FDA) approved Zepbound in November 2023 for weight management, following rigorous clinical trials demonstrating significant weight reduction when combined with reduced-calorie diet and increased physical activity. Tirzepatide works by mimicking two naturally occurring incretin hormones that regulate appetite, food intake, and glucose metabolism. By activating both GIP and GLP-1 receptors, the medication enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways.
It's important to understand that while "Zepbound" is the commercial name used in marketing and prescriptions, "tirzepatide" is the scientific nonproprietary name that appears on laboratory documentation, research publications, and insurance formularies. Currently, there is no FDA-approved generic (lower-cost interchangeable) version of tirzepatide available in the US market. Zepbound and Mounjaro (tirzepatide for type 2 diabetes) are distinct brand products with different FDA-approved indications and are not automatically substitutable.
Patients should be aware of important safety information: tirzepatide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tirzepatide is not indicated for type 1 diabetes and should not be used in combination with other GLP-1 receptor agonists.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
Tirzepatide is currently marketed under two primary brand names in the United States: Zepbound for chronic weight management and Mounjaro for type 2 diabetes mellitus. Both products contain the identical active ingredient—tirzepatide—manufactured by Eli Lilly and Company, but they carry distinct FDA-approved indications that determine their prescribed use.
There are no FDA-approved generic versions of tirzepatide in the US market at this time. However, patients may encounter several related terms:
LY3298176: The research designation used during clinical development phases
Tirzepatide injection: The generic descriptor that may appear on pharmacy labels
GIP/GLP-1 receptor agonist: The pharmacological class name used in medical literature
In the United States, tirzepatide is only available as the branded products Mounjaro and Zepbound. Patients should be aware that compounded versions of tirzepatide—preparations made by compounding pharmacies—are not FDA-approved products and differ significantly from the branded medications in terms of quality assurance, dosing precision, and regulatory oversight. The FDA has issued safety communications regarding concerns with compounded GLP-1 receptor agonist products.
When discussing tirzepatide with healthcare providers or pharmacists, using either the nonproprietary name "tirzepatide" or the specific brand name relevant to your indication ensures clear communication and reduces the risk of medication errors or insurance claim denials.
Despite containing identical active ingredients at the same dosage strengths, Zepbound and Mounjaro differ fundamentally in their FDA-approved indications, which determines how physicians can legally prescribe them. Mounjaro received FDA approval in May 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Zepbound was subsequently approved in November 2023 for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea.
The dosing schedules differ between indications. Mounjaro for diabetes typically starts at 2.5 mg subcutaneously once weekly, with potential escalation to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg based on glycemic response and tolerability. Zepbound for weight management begins at 2.5 mg weekly for four weeks, then increases to 5 mg, with possible further titration to 7.5 mg, 10 mg, 12.5 mg, or 15 mg at four-week intervals based on weight loss response and adverse effect tolerance. Maintenance doses for Zepbound are typically 5 mg, 10 mg, or 15 mg weekly.
Insurance coverage represents another critical distinction. Health plans may cover Mounjaro under diabetes medication benefits but may have different coverage policies for Zepbound, as coverage for weight management medications varies widely among insurers. This coverage disparity can lead to confusion among patients. The packaging, National Drug Code (NDC) numbers, and pricing structures also differ between the two brands. Patients should verify their specific insurance formulary status and prior authorization requirements before assuming coverage for either product. These products are not AB-rated in the FDA Orange Book and should not be substituted for one another without prescriber direction.
The existence of multiple names for the same pharmaceutical compound reflects standard practices in drug development, regulatory approval, and commercial marketing strategies. This naming convention serves several important functions in the healthcare system and pharmaceutical industry.
During research and development, pharmaceutical companies assign experimental codes—in tirzepatide's case, LY3298176—to track compounds through preclinical and clinical testing phases. Once a drug demonstrates safety and efficacy, the manufacturer selects a generic (nonproprietary) name following guidelines established by the United States Adopted Names (USAN) Council. This generic name—tirzepatide—provides a standardized identifier used globally in scientific literature, prescribing information, and regulatory documentation.
Brand names serve commercial and clinical purposes. Pharmaceutical companies trademark distinctive brand names to differentiate their products in the marketplace and communicate specific therapeutic applications to prescribers and patients. The decision to market tirzepatide under two separate brand names—Mounjaro and Zepbound—reflects a strategic approach to address distinct patient populations and clinical indications while navigating complex insurance reimbursement landscapes.
This multi-name approach also addresses regulatory requirements. The FDA approves medications for specific indications based on clinical trial evidence. By maintaining separate brands for diabetes and weight management, the manufacturer clearly delineates approved uses, facilitates appropriate prescribing, and manages distinct marketing claims for each indication. This separation helps prevent confusion about approved uses and supports compliance with FDA promotional regulations that prohibit manufacturers from marketing drugs for non-approved indications. While clinicians may prescribe medications off-label when clinically appropriate based on their professional judgment, pharmaceutical companies are restricted to promoting products only for FDA-approved indications.
Patients can reliably identify tirzepatide medications at the pharmacy by examining several key features on the prescription label and packaging. The most definitive identifier is the generic name "tirzepatide" which must appear on the pharmacy label alongside or instead of the brand name, depending on how the prescription was written and pharmacy labeling practices.
Physical characteristics of authentic tirzepatide products include:
Pre-filled single-dose pens: Both Zepbound and Mounjaro come as single-use injection pens, not multi-dose vials
Dosage strengths: Available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL injection
Manufacturer name: Eli Lilly and Company should appear on packaging
NDC numbers: Unique National Drug Code numbers specific to each strength and brand
The prescription label may include the indication—either for type 2 diabetes (Mounjaro) or weight management (Zepbound)—though this varies by pharmacy and state regulations. If the indication is not listed and you're unsure which product you've received, ask your pharmacist or prescriber for clarification.
Regarding storage: tirzepatide products require refrigeration between 36°F to 46°F (2°C to 8°C) until first use. After first use, the pen may be kept at room temperature up to 86°F (30°C) for up to 21 days. Do not freeze the medication and protect it from light.
Important safety considerations: If your pharmacy dispenses a compounded tirzepatide preparation, vial formulation, or product from an unfamiliar manufacturer, consult your pharmacist immediately. The FDA has issued warnings about counterfeit and compounded versions that may not meet quality standards. Always verify that your medication matches the prescribed brand name, comes in the expected pen device format, and includes complete manufacturer labeling with lot numbers and expiration dates. If you have concerns about medication authenticity, contact the manufacturer's patient support line or report suspected counterfeits to the FDA's MedWatch program.
The generic name for Zepbound is tirzepatide, which is the active pharmaceutical ingredient and nonproprietary name used in scientific literature and regulatory documentation.
Yes, both contain the identical active ingredient tirzepatide at the same dosage strengths, but they have different FDA-approved indications—Mounjaro for type 2 diabetes and Zepbound for chronic weight management—and should not be substituted without prescriber direction.
No, there are currently no FDA-approved generic versions of tirzepatide available in the US market. Patients should be cautious of compounded versions, which are not FDA-approved and differ in quality assurance and regulatory oversight.
All medical content on this blog is created using reputable, evidence-based sources and is regularly reviewed for accuracy and relevance. While we strive to keep our content current with the latest research and clinical guidelines, it is intended for general informational purposes only.
This content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider with any medical questions or concerns. Use of this information is at your own risk, and we are not liable for any outcomes resulting from its use.
